Loomis, Sayles & Company’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.79B | Sell |
4,003,821
-29,704
| -0.7% | -$13.9M | 2.41% | 12 |
|
|
2025
Q4 | $1.83B | Sell |
4,033,525
-88,603
| -2% | -$38.2M | 2.2% | 13 |
|
|
2025
Q3 | $1.61B | Buy |
4,122,128
+308,750
| +8% | +$129M | 1.92% | 15 |
|
|
2025
Q2 | $1.7B | Buy |
3,813,378
+65,047
| +2% | +$30M | 2.13% | 14 |
|
|
2025
Q1 | $1.82B | Sell |
3,748,331
-24,458
| -0.6% | -$11.4M | 2.63% | 11 |
|
|
2024
Q4 | $1.52B | Buy |
3,772,789
+704,575
| +23% | +$327M | 1.92% | 15 |
|
|
2024
Q3 | $1.43B | Sell |
3,068,214
-73,957
| -2% | -$35.5M | 1.87% | 13 |
|
|
2024
Q2 | $1.47B | Buy |
3,142,171
+31,743
| +1% | +$13.8M | 2.03% | 14 |
|
|
2024
Q1 | $1.3B | Sell |
3,110,428
-24,424
| -0.8% | -$10.3M | 1.85% | 15 |
|
|
2023
Q4 | $1.28B | Sell |
3,134,852
-28,616
| -0.9% | -$10.6M | 1.95% | 15 |
|
|
2023
Q3 | $1.1B | Sell |
3,163,468
-111,842
| -3% | -$39.1M | 1.89% | 15 |
|
|
2023
Q2 | $1.15B | Sell |
3,275,310
-96,336
| -3% | -$32.5M | 1.86% | 14 |
|
|
2023
Q1 | $1.06B | Sell |
3,371,646
-387,524
| -10% | -$116M | 1.84% | 16 |
|
|
2022
Q4 | $1.09B | Sell |
3,759,170
-399,220
| -10% | -$122M | 2.17% | 13 |
|
|
2022
Q3 | $1.2B | Sell |
4,158,390
-299,346
| -7% | -$86.1M | 2.44% | 14 |
|
|
2022
Q2 | $1.26B | Sell |
4,457,736
-1,931,287
| -30% | -$517M | 2.33% | 14 |
|
|
2022
Q1 | $1.67B | Sell |
6,389,023
-246,230
| -4% | -$58.4M | 2.23% | 15 |
|
|
2021
Q4 | $1.46B | Sell |
6,635,253
-370,739
| -5% | -$72.1M | 1.76% | 19 |
|
|
2021
Q3 | $1.27B | Buy |
7,005,992
+4,955,119
| +242% | +$967M | 1.56% | 21 |
|
|
2021
Q2 | $414M | Buy |
2,050,873
+2,049,877
| +205,811% | +$429M | 0.5% | 36 |
|
|
2021
Q1 | $214K | Buy |
996
+810
| +435% | +$178K | ﹤0.01% | 501 |
|
|
2020
Q4 | $44K | Sell |
186
-440
| -70% | -$101K | ﹤0.01% | 549 |
|
|
2020
Q3 | $170K | Buy |
626
+159
| +34% | +$43.9K | ﹤0.01% | 513 |
|
|
2020
Q2 | $136K | Sell |
467
-41
| -8% | -$11.1K | ﹤0.01% | 514 |
|
|
2020
Q1 | $121K | Buy |
508
+26
| +5% | +$5.96K | ﹤0.01% | 525 |
|
|
2019
Q4 | $106K | Buy |
+482
| New | +$97.5K | ﹤0.01% | 574 |
|
|
2014
Q3 | – | Sell |
-3,036,552
| Closed | -$288M | – | 754 |
|
|
2014
Q2 | $288M | Sell |
3,036,552
-423,328
| -12% | -$29.7M | 0.82% | 22 |
|
|
2014
Q1 | $245M | Sell |
3,459,880
-294,353
| -8% | -$23.3M | 0.69% | 28 |
|
|
2013
Q4 | $279M | Hold |
3,754,233
| – | – | 0.84% | 19 |
|
|
2013
Q3 | $285M | Sell |
3,754,233
-229,086
| -6% | -$18.2M | 0.92% | 17 |
|
|
2013
Q2 | $318K | Buy |
+3,983,319
| New | +$293M | 1.13% | 13 |
|
Other funds holding VRTX
VCM
VPM
Loomis, Sayles & Company's VRTX Position: Q1 2026 in Review
Loomis, Sayles & Company reduced its Vertex Pharmaceuticals (VRTX) stake by 0.74% in Q1 2026, selling an estimated $13.9M and leaving 4,003,821 shares worth $1.79B. The position accounts for 2.41% of the portfolio, ranked #12.
Loomis, Sayles & Company first reported a position in VRTX in Q2 2013 and has held it in 31 quarters since. The position peaked at $1.83B in Q4 2025. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Loomis, Sayles & Company held 4,003,821 shares of Vertex Pharmaceuticals worth $1.79B as of Q1 2026.
- Loomis, Sayles & Company sold 29,704 Vertex Pharmaceuticals shares in Q1 2026, an estimated $13.9M.
- Vertex Pharmaceuticals made up 2.41% of Loomis, Sayles & Company's portfolio in Q1 2026, its #12 holding.
- Loomis, Sayles & Company first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 31 quarters since.
- Loomis, Sayles & Company's Vertex Pharmaceuticals position peaked at $1.83B in Q4 2025.
- 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Loomis, Sayles & Company's 13F filing for Q1 2026, filed 14 May 2026.